Literature DB >> 7625805

Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37.

G S Pari1, A K Field, J A Smith.   

Abstract

An antisense phosphorothioate oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37 (UL36ANTI) reduced the yield of infectious virus by 99% and inhibited human cytomegalovirus DNA replication at a concentration of 0.08 microM. In addition, oligonucleotides with base substitutions which resulted in base pair mismatches showed lesser degrees of activity, indicating a sequence-specific antisense mechanism. UL36ANTI was also shown to inhibit DNA replication of ganciclovir-resistant strains and human cytomegalovirus clinical isolates.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7625805      PMCID： PMC162700          DOI： 10.1128/AAC.39.5.1157

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  A simple and fast method to extract RNA from tissue culture cells.

Authors:  K Peppel; C Baglioni
Journal:  Biotechniques       Date:  1990-12       Impact factor: 1.993

2.  Expression of the human cytomegalovirus UL36-38 immediate early region during permissive infection.

Authors:  D J Tenney; A M Colberg-Poley
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

Review 3.  Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.

Authors:  M S Chee; A T Bankier; S Beck; R Bohni; C M Brown; R Cerny; T Horsnell; C A Hutchison; T Kouzarides; J A Martignetti
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

4.  Regulation of cytomegalovirus late-gene expression: differential use of three start sites in the transcriptional activation of ICP36 gene expression.

Authors:  F S Leach; E S Mocarski
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine.

Authors:  W Y Gao; J W Jaroszewski; J S Cohen; Y C Cheng
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

6.  Herpes simplex virus type 1 gene products required for DNA replication: identification and overexpression.

Authors:  P D Olivo; N J Nelson; M D Challberg
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides.

Authors:  W Y Gao; R N Hanes; M A Vazquez-Padua; C A Stein; J S Cohen; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Human cytomegalovirus UL36-38 and US3 immediate-early genes: temporally regulated expression of nuclear, cytoplasmic, and polysome-associated transcripts during infection.

Authors:  D J Tenney; A M Colberg-Poley
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

10.  Human cytomegalovirus US3 and UL36-38 immediate-early proteins regulate gene expression.

Authors:  A M Colberg-Poley; L D Santomenna; P P Harlow; P A Benfield; D J Tenney
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103
View more
  11 in total

1.  Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli.

Authors:  P Trang; M Lee; E Nepomuceno; J Kim; H Zhu; F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  Strategy for designing specific antisense oligonucleotide sequences.

Authors:  M Mitsuhashi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

Review 4.  Viral product trafficking to mitochondria, mechanisms and roles in pathogenesis.

Authors:  Chad D Williamson; Roberta L DeBiasi; Anamaris M Colberg-Poley
Journal:  Infect Disord Drug Targets       Date:  2012-02

5.  Evidence that the UL84 gene product of human cytomegalovirus is essential for promoting oriLyt-dependent DNA replication and formation of replication compartments in cotransfection assays.

Authors:  R T Sarisky; G S Hayward
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Murine cytomegalovirus containing a mutation at open reading frame M37 is severely attenuated in growth and virulence in vivo.

Authors:  M Lee; J Xiao; E Haghjoo; X Zhan; G Abenes; T Tuong; W Dunn; F Liu
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs.

Authors:  D G White; K Maneewannakul; E von Hofe; M Zillman; W Eisenberg; A K Field; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  The human cytomegalovirus UL37 immediate-early regulatory protein is an integral membrane N-glycoprotein which traffics through the endoplasmic reticulum and Golgi apparatus.

Authors:  H O Al-Barazi; A M Colberg-Poley
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 9.  Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.

Authors:  Beatrice Mercorelli; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Pharmacol Ther       Date:  2011-04-28       Impact factor: 12.310

10.  Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.

Authors:  M D de Jong; C A Boucher; D A Cooper; G J Galasso; B Gazzard; J M Lange; J S Montaner; D D Richman; H C Thomas
Journal:  Antiviral Res       Date:  1997-07       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.